KRAS and non-small cell lung carcinoma: In a phase 2 single-arm trial in China evaluating 119 patients with locally advanced or metastatic KRAS G12C-mutated NSCLC who had progressed on platinum-based chemoimmunotherapy, glecirasib demonstrated an ORR of 47% and median PFS of 8.2 months (95% CI, 5.5–13.1) [25].